

**CONTRACT UPDATES**

**SERVICE AGREEMENTS**

**PRODUCT AGREEMENTS**



## Taxotere® Market Share Submission Reminder

According to the OA group contract terms, in order for an individual practice to receive a discount for all Taxotere® purchases, you must report your market share data to the Aventis Taxotere Market Share web site. This site will enable you to report your quarterly purchases, credits/returns for all products within the Taxotere® Therapeutic Category (Taxotere®, paclitaxel and gemcitabine).

**To access the website, type the following address: <http://taxotere.custservices.com/>  
You will need to submit data on a quarterly basis. Submission deadlines are as follows:**

- > Q3, 2004: Due By November 15, 2004
- > Q4, 2004: Due By February 15, 2005

If you do not have Internet or email access or need a password, please call the Aventis customer assistance number (866-278-1903) immediately for instructions on how to proceed. If you have any questions regarding this program, contact Oncology Associates at 888-732-7352. Thank you for your participation!

### RECENT PRODUCT NEWS

## Kadian® for Cancer Pain

MGI PHARMA, INC., an oncology-focused biopharmaceutical company, announced that it has entered into a three year agreement with Alpharma, Inc. to promote Alpharma's sustained release morphine sulfate product, Kadian®. Under the terms of this promotion agreement, MGI PHARMA will market Kadian® in the United States to oncology health care professionals for moderate to severe pain associated with cancer. Kadian® is currently marketed by Alpharma to pain specialists in the United States.

"The majority of cancer patients experience pain as a symptom during the course of cancer treatment, and we believe Kadian has the opportunity to play an important role in the oncology-related pain market," said Ed Rubenstein, Senior Vice President, Medical and Commercial Development at MGI PHARMA. "The convenience of Kadian's® once or twice per day dosing profile combined with the availability of several dosage strengths may better enable cancer clinicians to consistently manage cancer patients' pain."

The above information was taken from an MGI PHARMA, INC. press release available on the company web site at [www.mgipharma.com](http://www.mgipharma.com). Contact your local MGI PHARMA representative for more information about Kadian®.



## New Agreement for ZOMETA®

Oncology Associates is pleased to announce ZOMETA® (zoledronic acid) has been added to the Novartis agreement, effective **October 1, 2004**. The agreement will run until December 31, 2004.

ZOMETA® is offered to all OA members in good standing at a **significant discount of 5%**. The product is available in 4 mg/5ml vials.

ZOMETA® Injection is indicated for the treatment of hypercalcemia of malignancy. ZOMETA® is also indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.

Contact Oncology Associates at **888-732-7352** with any questions about the Novartis agreement. For more information about ZOMETA®, visit [www.zometa.com](http://www.zometa.com).

NDC#	Strength	Discount
0078-0387-25	4mg/ 5mL vial	5%

(1 Vial per package)

## Sandostatin LAR® Rebates Released

As part of the OA product agreement for Sandostatin LAR®, we are pleased to announce the release of April and May 2004 rebate checks. Eligible members should have already received these checks, as they were issued on August 23, 2004 (April) and September 2, 2004 (May).

Rebates are earned on a monthly basis with the resulting checks sent to the practice at approximately 90 days from the end of each month.

This OA agreement with Novartis currently runs from **April 1, 2004 through December 31, 2004**. Contact Oncology Associates at **888-732-7352** with any questions regarding this agreement or the rebates earned.